Predictors of postoperative remission of acromegaly. (Experience of the Burdenko Neurosurgical Center)

Astafieva LI, Shkarubo AN, Chernov IV, et al. . Predictors of postoperative remission of acromegaly. (Experience of the Burdenko Neurosurgical Center). Burdenko's Journal of Neurosurgery. 2023;87(6):76‑84. (In Russ., In Engl.)
https://doi.org/10.17116/neiro20238706176

Подписка 2025 Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко (Burdenko's Journal of Neurosurgery)

Использование инфографики авторами научных работ

Close metadata

BACKGROUND

Treatment of acromegaly is still an unresolved problem. Overall postoperative remission rate ranges from 34 to 85%. These values are better for microadenomas (75—90%) and worse for macroadenomas (45—70%). Identification of predictors of acromegaly remission after surgical treatment is an urgent objective to improve the quality of medical care for these patients.

OBJECTIVE

To analyze postoperative freedom from acromegaly and predictors of remission.

MATERIAL AND METHODS

A retrospective single-center study included 227 patients with acromegaly who underwent resection of pituitary adenoma between August 2018 and August 2021.

RESULTS

Remission (normalization of serum IGF-1) was achieved in 65 (55%) patients. Growth hormone and IGF-1 index decreased after surgery in all patients. Mean preoperative serum growth hormone was 12.45 [6.88, 29.85] ng/ml, early postoperative concentration — 1.54 [0.80, 3.38] ng/ml, in delayed period — 1.15 [0.57, 3.80] ng/ml. Mean IGF-1 index was 2.18 [1.69, 2.71], 1.47 [0.99, 1.90] and 0.99 [0.74, 1.43], respectively.

CONCLUSION

Significant predictors of acromegaly remission after neurosurgical treatment were age, preoperative level of growth hormone, tumor size and location, growth hormone and IGF-1 index in early postoperative period and residual tumor after surgery. Multivariate analysis revealed a significant association of acromegaly remission with small tumor size, low postoperative level of growth hormone and no residual tumor within 3—6 month after surgery.

Keywords:

acromegaly

growth hormone

pituitary adenoma

endoscopic transnasal resection of pituitary adenoma

Authors:

Astafieva L.I.

Burdenko Neurosurgical Center

ORCID: 0000-0003-4480-1902

Shkarubo A.N.

Burdenko Neurosurgical Center

ORCID: 0000-0003-3445-3115

Chernov I.V.

Burdenko Neurosurgical Center

ORCID: 0000-0002-9789-3452

Ibrahim S.R.

People’s Friendship University of Russia

ORCID: 0000-0002-6233-9929

Badmaeva I.N.

Burdenko Neurosurgical Center

ORCID: 0000-0003-2211-4298

Strunina Yu.V.

Burdenko Neurosurgical Center

ORCID: 0000-0003-1696-4050

Ilovayskaya I.A.

M.F. Vladimirsky Moscow Regional Research Clinical Institute

ORCID: 0000-0003-3261-7366

Pronin V.S.

Russian Medical Academy of Continuing Professional Education

ORCID: 0000-0001-5045-798X

Sidneva Yu.G.

Burdenko Neurosurgical Center;
Research Institute for Emergency Pediatric Surgery and Traumatology

ORCID: 0000-0003-2733-5874

Kalinin P.L.

Burdenko Neurosurgical Center

ORCID: 0000-0001-9333-9473

Received:

17.06.2023

Accepted:

14.09.2023

Close metadata

References:

Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A. Guidelines for Acromegaly Management: An Update. The Journal of Clinical Endocrinology and Metabolism. 2009;94:1509-1517. https://doi.org/10.1210/jc.2008-2421
Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JAH, Giustina A. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16:294-302. https://doi.org/10.1007/s11102-012-0420-x
Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF, Clemmons D, Colao A, Ferone D, Fleseriu M, Frara S, Gadelha MR, Ghigo E, Gurnell M, et al. A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. The Journal of Clinical Endocrinology and Metabolism. 2020;105:937-946. https://doi.org/10.1210/clinem/dgz096
Burton T, Le Nestour E, Bancroft T, Neary M. Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary. 2013;16:354-362. https://doi.org/10.1007/s11102-012-0432-6
Wang YY, Higham C, Kearney T, Davis JRE, Trainer P, Gnanalingham KK. Acromegaly surgery in Manchester revisited — The impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clinical Endocrinology. 2012;76:399-406. https://doi.org/10.1111/j.1365-2265.2011.04193.x
Buchfelder M, Schlaffer S-M. The surgical treatment of acromegaly. Pituitary. 2017;20:76-83. https://doi.org/10.1007/s11102-016-0765-7
Belaya ZE, Golounina OO, Rozhinskaya LY, Melnichenko GA, Isakov MA, Lutsenko AS, Alekseeva T, Zenkova TS, Przhiyalkovskaya EG, Panyushkina GM, Ilukhina OB, Ivanova EI, Krishtal EA, Vachygova AA, Pigarova EA, Dzeranova LK, Marova EI, Arapova SD, et al. Epidemiology, clinical manifestations and efficiency of different methods of treatment of acromegaly according to the United Russian Registry of Patients with Pituitary Tumors. Problems of Endocrinology. 2020;66:93-103. (In Russ.). https://doi.org/10.14341/probl10333
Starnoni D, Daniel RT, Marino L, Pitteloud N, Levivier M, Messerer M. Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. Acta Neurochirurgica. 2016;158:2109-2121. https://doi.org/10.1007/s00701-016-2903-4
Jane JA, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, Marshall JC, Laws ER, Vance ML. Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome. The Journal of Clinical Endocrinology and Metabolism. 2011;96:2732-2740. https://doi.org/10.1210/jc.2011-0554
Sarkar S, Chacko AG. Surgery for Acromegaly. Neurology India. 2020;68:44-51. https://doi.org/10.4103/0028-3886.287664
Agrawal N, Ioachimescu AG. Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review. Pituitary. 2020;23:582-594. https://doi.org/10.1007/s11102-020-01063-x
Fougner SL, Bollerslev J, Svartberg J, Øksnes M, Cooper J, Carlsen SM. Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. European Journal of Endocrinology. 2014;171:229-235. https://doi.org/10.1530/EJE-14-0249
Li Z-Q, Quan Z, Tian H-L, Cheng M. Preoperative Lanreotide Treatment Improves Outcome in Patients with Acromegaly Resulting from Invasive Pituitary Macroadenoma. Journal of International Medical Research. 2012;40:517-524. https://doi.org/10.1177/147323001204000213
Mao Z, Zhu Y, Tang H, Wang D, Zhou J, He D, Lan H, Luo B, Wang H. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. European Journal of Endocrinology. 2010;162:661-616. https://doi.org/10.1530/EJE-09-0908
Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis. The Journal of Clinical Endocrinology and Metabolism. 2005;90:4465-4473. https://doi.org/10.1210/jc.2005-0260